This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Psyrri, A. Articles by Dimopoulos, M. A. Search for Related Content PubMed PubMed Citation Articles by Psyrri, A. Articles by Dimopoulos, M. A.

Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer

Authors' Affiliations: Departments of ¹ Medical Oncology and ² Pathology, Yale University School of Medicine, New Haven, Connecticut and Departments of ³ Clinical Therapeutics and ⁴ Pathology, University of Athens School of Medicine, Athens, Greece

Requests for reprints: Amanda Psyrri, Yale Cancer Center, P.O. Box 208032, New Haven, CT 06520. Phone: 203-737-2476; Fax: 203-785-7531; E-mail: diamando.psyrri{at}yale.edu.

Background: Several lines of laboratory evidence support the epidermal growth factor receptor (EGFR) as an adverse prognostic indicator in ovarian cancers. However, different methods of immunohistochemical assessment have yielded conflicting results. Here, we sought to determine the prognostic value of EGFR in ovarian cancer using a novel method of compartmentalized in situ protein analysis.

Methods: A tissue array composed of 150 advanced-stage ovarian cancers uniformly treated, with surgical debulking followed by platinum-paclitaxel combination chemotherapy, was constructed. For evaluation of EGFR protein expression, we used an immunofluorescence-based method of automated in situ quantitative measurement of protein analysis (AQUA).

Results: Mean follow-up time for the entire cohort was 34.4 months. Eighty-one of 150 cases had sufficient tissue for AQUA analysis. High tumor EGFR expression was associated with poor outcome for overall survival (P = 0.0001) and disease-free survival (P = 0.0005) at 3 years. In multivariable analysis, adjusting for well-characterized prognostic variables, EGFR expression status was the most significant prognostic factor for disease-free and overall survival.

Conclusion: The conflicting results in the literature regarding the prognostic value of EGFR may be due to the technical difficulties inherent in assessing EGFR with immunocytochemistry. In the present study, we show that measurement of EGFR protein levels in ovarian cancer using AQUA is feasible and can give important prognostic information.

This article has been cited by other articles:

				A. Psyrri, P. Kountourakis, A. Scorilas, S. Markakis, R. Camp, D. Kowalski, E. P. Diamandis, and M. A. Dimopoulos Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression Ann. Onc., July 1, 2008; 19(7): 1271 - 1277. [Abstract] [Full Text] [PDF]

				K. D. Cowden Dahl, J. Symowicz, Y. Ning, E. Gutierrez, D. A. Fishman, B. P. Adley, M. S. Stack, and L. G. Hudson Matrix Metalloproteinase 9 Is a Mediator of Epidermal Growth Factor-Dependent E-Cadherin Loss in Ovarian Carcinoma Cells Cancer Res., June 15, 2008; 68(12): 4606 - 4613. [Abstract] [Full Text] [PDF]

				K. D. Steffensen, M. Waldstrom, D. A. Olsen, T. Corydon, K. A. Lorentzen, H. J. Knudsen, U. Jeppesen, I. Brandslund, and A. Jakobsen Mutant Epidermal Growth Factor Receptor in Benign, Borderline, and Malignant Ovarian Tumors Clin. Cancer Res., June 1, 2008; 14(11): 3278 - 3282. [Abstract] [Full Text] [PDF]

				D. Mezzanzanica, M. Fabbi, M. Bagnoli, S. Staurengo, M. Losa, E. Balladore, P. Alberti, L. Lusa, A. Ditto, S. Ferrini, et al. Subcellular Localization of Activated Leukocyte Cell Adhesion Molecule Is a Molecular Predictor of Survival in Ovarian Carcinoma Patients Clin. Cancer Res., March 15, 2008; 14(6): 1726 - 1733. [Abstract] [Full Text] [PDF]

				Q. S.C. Chu, G. Schwartz, J. de Bono, D. A. Smith, K. M. Koch, M. J. Versola, L. Pandite, N. Arya, J. Curtright, R. A. Fleming, et al. Phase I and Pharmacokinetic Study of Lapatinib in Combination With Capecitabine in Patients With Advanced Solid Malignancies J. Clin. Oncol., August 20, 2007; 25(24): 3753 - 3758. [Abstract] [Full Text] [PDF]

				Z. Duan, R. Foster, D. A. Bell, J. Mahoney, K. Wolak, A. Vaidya, C. Hampel, H. Lee, and M. V. Seiden Signal Transducers and Activators of Transcription 3 Pathway Activation in Drug-Resistant Ovarian Cancer Clin. Cancer Res., September 1, 2006; 12(17): 5055 - 5063. [Abstract] [Full Text] [PDF]